Trials / Conditions / Thrombotic Microangiopathies

Thrombotic Microangiopathies

25 registered clinical trials studyying Thrombotic Microangiopathies — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	TGD001 Treatment in Thrombotic Microangiopathies NCT07459114	TargED Biopharmaceuticals B.V.	Phase 1 / Phase 2
Recruiting	Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center NCT07205861	Assistance Publique - Hôpitaux de Paris	—
Recruiting	Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669	Peking University People's Hospital	—
Withdrawn	Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma NCT06182410	University of California, San Francisco	Phase 2
Recruiting	Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange NCT06291025	University Hospital, Rouen	N/A
Withdrawn	The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune NCT06291415	Hutchmed	Phase 1
Recruiting	Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy NCT06102694	Institute of Hematology & Blood Diseases Hospital, China	—
Unknown	Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study NCT05996679	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Unknown	Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab NCT06098378	University Hospital, Strasbourg, France	—
Recruiting	Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transpla NCT05855083	Omeros Corporation	Phase 2
Unknown	Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-in NCT05702996	University Hospital, Rouen	Phase 3
Recruiting	Construction of a Database for TMA NCT05634928	The First Affiliated Hospital of Soochow University	—
Recruiting	TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients NCT04098445	Children's Hospital Medical Center, Cincinnati	—
Recruiting	Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium NCT04745195	Maastricht University Medical Center	—
Withdrawn	Study in Adult and Pediatric Patients With HSCT-TMA NCT04970004	Alexion Pharmaceuticals, Inc.	—
Terminated	Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy NCT04784455	AKARI Therapeutics	Phase 3
Unknown	Ravulizumab and COVID-19 NCT04570397	Brigham and Women's Hospital	Phase 3
Unknown	TTP and aHUS in Complicated Pregnancies NCT03605511	University College, London	—
Completed	Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ D NCT03518203	Children's Hospital Medical Center, Cincinnati	Phase 2
Terminated	Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome NCT03205995	Omeros Corporation	Phase 3
Completed	Defibrotide TMA Prophylaxis Pilot Trial NCT03384693	University of California, San Francisco	Phase 2
Completed	A Safety and Efficacy Study of NAC in Patients With TA-TMA NCT03252925	The First Affiliated Hospital of Soochow University	Phase 3
Unknown	Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) NCT02373267	University of Cologne	—
Completed	Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies NCT02222545	Omeros Corporation	Phase 2
Completed	Early Predictive Factors of Cardiac and Cerebral Involvement in TMA NCT02134171	Assistance Publique - Hôpitaux de Paris	N/A